Naran Sanjay, Zhang Xinglu, Hughes Steven J
University of Pittsburgh School of Medicine, Division of Surgical Oncology, Department of Surgery, Pittsburgh, PA 15261, USA.
Expert Opin Ther Targets. 2009 May;13(5):569-81. doi: 10.1517/14728220902853917.
Inhibition of inappropriate tyrosine kinase activity by neoplasms is an attractive strategy for the treatment of malignancy.
We aimed to produce a concise review of the potential role of hepatocyte growth factor (HGF)/Mesenchymal-epithelial transition factor (MET) tyrosine kinase pathway inhibition in the treatment of cancer.
The current literature, abstracts and internet resources related to HGF/MET structure, function and inhibition are summarized. The potential of inhibiting this pathway as a therapy for cancer and remaining hurdles prior to routine clinical use of MET inhibition are discussed.
RESULTS/CONCLUSIONS: Current knowledge suggests that the inhibition of the HGF/MET pathway has significant potential for the treatment of cancer. A number of MET inhibitor molecules are nearing completion of their development for clinical use.
抑制肿瘤中不适当的酪氨酸激酶活性是治疗恶性肿瘤的一种有吸引力的策略。
我们旨在简要综述肝细胞生长因子（HGF）/间充质上皮转化因子（MET）酪氨酸激酶途径抑制在癌症治疗中的潜在作用。
总结了与HGF/MET结构、功能和抑制相关的当前文献、摘要和网络资源。讨论了抑制该途径作为癌症治疗方法的潜力以及在MET抑制常规临床应用之前尚存的障碍。
结果/结论：目前的知识表明，抑制HGF/MET途径在癌症治疗中具有巨大潜力。一些MET抑制剂分子已接近完成临床应用开发。
